timolol maleate ophthalmic solution / Generic mfg. - LARVOL DELTA

Integrating contrast sensitivity and vascular resistance into a nomogram to predict postoperative treatment outcomes in primary glaucoma. (PubMed, Eur J Med Res) - "The nomogram model accurately predicts treatment outcomes after primary glaucoma surgery, showing strong discriminative ability and calibration. It may assist clinicians in personalizing postoperative treatment strategies. Further large-sample, multicenter studies are warranted for validation and broader application."

Journal • Retrospective data • Glaucoma • Ophthalmology

Nimodipine Nanoparticles: A Promising Approach for Glaucoma Management. (PubMed, Pharmaceutics) - "Background/Objectives: Glaucoma is a multifactorial eye disease that can cause optic nerve damage and irreversible blindness. After a single topical ocular application, NMD-MCS NP eye drops induced a significantly superior effect to Timolol maleate eye drops with regard to the %IOP reduction and duration of action. Evaluation results of NMD-CS NP eye drops show their positive effect in a preclinical animal model as a promising glaucoma therapy."

Journal • Glaucoma • Ophthalmology

Fabrication and Evaluation of PLGA Microsphere-Loaded Hydrogels as Potential Intraocular Lens for Sustained Release of Timolol Maleate. (PubMed, Mol Pharm) - "Moreover, the incorporation of PLGA microspheres into the PAH film slows PLGA degradation, resulting in a 3-fold increase in release duration when compared to that of standalone microspheres. The resulting system ensures a long-term, patient-friendly approach to glaucoma treatment."

Journal • Cataract • Glaucoma • Ophthalmology

Clinical characteristics, treatment outcomes and prognostic factors of ulcerated infantile hemangioma: 15 years of experience from a pediatric dermatology center in Hong Kong. (PubMed, J Dermatolog Treat) - "Combination therapy with oral propranolol and pulsed dye laser was the mainstay of treatment (74%). Early referral of high-risk cases to a pediatric dermatology center before ulceration is crucial. Prophylactic topical timolol before ulceration and maintenance laser therapy after ulcer resolution can improve outcomes."

Biomarker • Journal • Dermatology • Pediatrics

Refractory ulcerations treated with timolol due to bullous pemphigoid in the setting of chronic cutaneous graft-versus-host disease. (PubMed, JAAD Case Rep) - No abstract available

Journal • Bone Marrow Transplantation • Bullous Pemphigoid • Dermatology • Dermatopathology • Graft versus Host Disease • Immunology • Transplantation

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2 | N=228 | Recruiting | Sponsor: Bausch & Lomb Incorporated | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Double-Masked Controlled Trial of H-1337 as a Treatment for Glaucoma and Ocular Hypertension. (PubMed, J Ocul Pharmacol Ther) - " H-1337 in doses of 0.6% b.i.d., 1.0% q.d., and 1.0% b.i.d. had ocular hypotensive efficacy in the range of timolol, although not within the strict Phase 3 non-inferiority margins, which would have required a larger sample size."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Reactive angioendotheliomatosis as a side effect of long-acting injectable insulin use. (PubMed, Dermatol Online J) - "The patient was switched to a glucagon-like peptide-1 agonist, active lesions were treated with topical timolol 0.5% ophthalmic solution, and oral propranolol was started with upward titration. She continues to see improvement in pain and has not developed any new ulcerations at other sites on the body."

Adverse events • Journal • Diabetes • Immunology • Metabolic Disorders • Mood Disorders • Ophthalmology • Pain • Type 2 Diabetes Mellitus

Gellan gum/gelatin Schiff-base hydrogel for ocular drug delivery of timolol maleate. (PubMed, BMC Biotechnol) - "Also, the MTT cytotoxicity test on bone marrow mesenchymal stem cells (BMSCs) confirmed that the developed hydrogels with green crosslinker do not have cytotoxic effects. In vitro and ex vivo drug release tests demonstrated a facile preparation strategy for fast-gelling hydrogels that can be considered as an appropriate candidate for timolol maleate delivery in glaucoma treatment."

Journal • Glaucoma • Ophthalmology

When Relief Becomes a Reaction: Timolol-Linked Periorbital Dermatitis. (PubMed, Dermatitis) - No abstract available

Journal • Dermatitis • Dermatology • Immunology

Structural and Pharmacological Insights into Propranolol: An Integrated Crystallographic Perspective. (PubMed, Int J Mol Sci) - "Comparative structural analysis with other β-blockers-alprenolol, timolol, and carvedilol-highlights how variations in aromatic and heterocyclic frameworks influence pharmacokinetics and receptor selectivity. These findings underscore the importance of propranolol's amphiphilic character, stereochemistry, and electrostatic properties in shaping its pharmacological profile. Overall, the integration of crystallographic data with pharmacological insights supports the rational design of next-generation β-adrenergic ligands with enhanced selectivity, bioavailability, and clinical efficacy."

Journal • Review • Cardiovascular • CNS Disorders • Hypertension • Migraine • Mood Disorders • Pain • Psychiatry

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: SpyGlass Pharma, Inc.

New P3 trial • Cardiovascular • Cataract • Glaucoma • Ophthalmology

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: SpyGlass Pharma, Inc.

New P3 trial • Cardiovascular • Cataract • Glaucoma • Ophthalmology

Corchorus olitorius-derived green carbon dots: A single nanomaterial for multiplexed applications in sensing, catalysis, and critical micelle concentration analysis. (PubMed, Talanta) - "As a nanosensor, the N-CDs enable the highly sensitive detection of the antiglaucoma drug timolol maleate (TIM) via a fluorescence quenching mechanism, achieving a remarkable limit of detection (LOD) as low as 0.49 μM...Furthermore, the N-CDs function as an efficient fluorescent thermosensor across a physiologically relevant range (30-70 °C), a facile probe for determining the CMC of surfactants, and a potent visible-light-driven photocatalyst for methylene blue degradation. This work pioneers a sustainable path for converting biomass into high-value-added N-CDs, providing a cost-effective and environmentally friendly multifunctional nanoprobe aligned with sustainable development goals."

Journal • Glaucoma • Ophthalmology

In Vivo Comparison of Intracameral and Intravitreal Implantation of a Timolol Maleate Miniaturized Injectable Delivery System Device. (PubMed, Ophthalmol Sci) - "Intravitreal and IC devices showed similar IOP reductions; IVT injection led to a higher drug concentration in the target ciliary body tissue, and in normotensive rabbit eyes showed general reduction of IOP over 8 weeks, indicating the potential of MIDS technology to address issues of patient adherence with glaucoma eye drops. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Preclinical • Glaucoma • Inflammation • Ophthalmology

Spectroscopic and Chemometric Evaluation of the Stability of Timolol, Naphazoline, and Diflunisal in the Presence of Reactive Excipients Under Forced Degradation Conditions. (PubMed, Molecules) - "A hybrid approach, combining visual assessment with chemometric evaluation of the spectral data, enabled the detection of changes that were not clearly observable using a single analytical method. In particular, interactions of TIM, NAPH, and DIF with MAN and TRIS were clearly identified, while the mixtures of NAPH with excipients proved to be the least sensitive to forced degradation."

Journal

Efficacy of 0.25% Timolol Gel in Healing Surgical Open Wounds: A Randomized Clinical Trial. (PubMed, J Am Acad Dermatol) - No abstract available

Clinical • Journal • Dermatology

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3 | N=28 | Terminated | Sponsor: University of Miami | N=500 ➔ 28 | Completed ➔ Terminated; No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.

Enrollment change • Trial termination • Glaucoma • Ophthalmology

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: University of Maryland, Baltimore | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Glaucoma • Ophthalmology

Topical Timolol for the Healing of Complex Ulcers (EADV 2025) - "Topical timolol proved to be a valuable therapeutic adjunct in chronic microvascular ulcers, promoting wound healing and pain control, even in patients with severe systemic comorbidities. Its ease of application, excellent local tolerance, affordability, and minimal systemic absorption make it particularly suitable in fragile populations. This case series highlights the potential role of timolol in managing complex ulcers, justifying further investigation through larger, controlled clinical studies."

Calciphylaxis • Cardiovascular • Chronic Kidney Disease • Dermatitis • Dermatology • Diabetes • Diabetic Nephropathy • Dyslipidemia • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Ophthalmology • Rare Diseases • Renal Disease • Scleroderma • Systemic Sclerosis • Thrombosis

Clinicodemographic Determinants and Therapeutic Outcomes in Infantile Hemangiomas: A 10-Year Retrospective Cohort Study (EADV 2025) - "Oral beta-blockers (propranolol or atenolol) were used in 35.4% of cases, while 27.9% received topical timolol. This study underscores the importance of therapy duration and lesion location in determining IH treatment outcomes. While beta-blockers remain highly effective, responses vary significantly based on lesion complexity and anatomical distribution. The findings support the need for individualized treatment strategies and highlight the limitations of a one-size-fits-all approach."

Retrospective data • Pediatrics

Paronychia in Selumetinib-treated patients (EADV 2025) - "After six weeks (T1), 55% of patients had complete resolution and discontinued therapy, while non-responders received second-line treatments, including continued clobetasol, timolol gel, or intralesional triamcinolone acetonide. Clobetasol under occlusion proved effective in treating paronychia, achieving complete resolution in 55% of patients at six weeks, with improved outcomes at twelve weeks. Second-line therapies yielded only partial responses. Selumetinib can cause significant dermatological complications, sometimes requiring dose adjustment or discontinuation."

Clinical • Genetic Disorders • Neurofibromatosis • Pediatrics • Solid Tumor • MAP2K1 • NF1

Efficacy of Topical Timolol 0.5% in the Treatment of Post-Acne Erythema: A Pilot Study in Ten Patients (EADV 2025) - "This pilot study supports the hypothesis that topical timolol 0.5% solution helps in improvement in erythema observed in nine of ten participants, combined with minimal adverse effect. The small sample size, open- label design, and lack of a control group restrict the generalizability of the findings are the limitations of study."

Clinical • Acne Vulgaris • Cardiovascular • Dermatology • Immunology • Ophthalmology • Rosacea

Comparative Efficacy of 1% Timolol in Treating Infantile Hemangiomas with Deep Growth Tendencies: Topical Application vs. Occlusive Compresses (EADV 2025) - "Occlusive compresses with 1% timolol represent a more effective, non-invasive treatment option for subcutaneous IHs compared to conventional application. The occlusion-enhanced transdermal drug delivery offers a significant therapeutic advantage, particularly when systemic beta-blockers are contraindicated or declined."

Clinical • Vasculitis

A Novel Classification of Infantile Hemangioma Growth Patterns and Its Clinical Implications for Tailored Topical Timolol Therapy (EADV 2025) - "Expanding the conventional IH classification to include the peripheral subtype enhances clinical decision-making and facilitates more targeted, non-invasive treatment strategies. This four-pattern approach supports individualized care and is particularly advantageous in outpatient and remote care settings."

Clinical • Vasculitis